These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Long acting injectable hormonal contraceptives.
    Author: Fraser IS.
    Journal: Clin Reprod Fertil; 1982 Mar; 1(1):67-88. PubMed ID: 6226351.
    Abstract:
    Injectable hormonal preparations can be highly effective and satisfactory contraceptives. The two main preparations available today are depot medroxy progesterone acetate (DMPA) and norethisterone oenanthate (NET-OEN), but several other approaches are currently under clinical trial. Injectable contraceptives have some unique advantages which give them justifiably wide appeal amongst many groups of women. However, they do have a number of disadvantages including invariable menstrual disturbance and a delay in the return of fertility. One formulation of DMPA, Depo-Provera, is probably the most extensively investigated single hormonal contraceptive ever made. These studies indicate that it is remarkably safe and does not face any more unresolved issues than the combined pill, intrauterine device or tubal sterilization. However, for a number of disparate emotional and political reasons it has attracted the attention of several consumer and feminist groups, who have waged a prolonged and quite unjustified campaign against it. It is to be hoped that future debate will be conducted on a more informed, rational and less emotional basis. Injectable contraceptives should have an important place in the family planning armamentarium of all countries, and current developments should lead to a decrease in concerns about presently available agents. This should further increase the widespread acceptability of this approach to contraception. Injectable hormonal preparations can be highly effective and satisfactory contraceptives. The 2 main preparations available today are depo medroxyprogesterone acetate (DMPA) and norethindrone enanthate (NET-EN), but several other approaches are currently under clinical trial. Injectable contraceptives have some unique advantages which give them justifiably wide appeal among many groups of women. However, they do have a number of disadvantages including invariable menstrual disturbance and a delay in return to fertility. 1 DMPA formulation, Depo-Provera, is probably the most extensively investigated single hormonal contraceptive ever made. These studies indicate that it is remarkably safe and does not appear to be an unresolved issue any more than the combined pill, the IUD, or tubal sterilization. However, for a number of disparate emotional and political reasons, it has attracted the attention of several consumer and feminist groups, who have waged a prolonged and highly unjustified campaign against it. It is hoped that future debate will be conducted on a more informed, rational, and less emotional basis. Injectable contraceptives should have an important place in the family planning programs of all countries, and current developments should lead to a drop in concerns about those agents presently available. This should further increase the widespread acceptability of this approach to contraception.
    [Abstract] [Full Text] [Related] [New Search]